We report a 62-year-old male who underwent non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) because of his life-threatening severe pancytopenia due to refractory Waldenström's macroglobulinemia. This therapy was performed safely and he made a marked recovery from his cytopenia that had not been improved with any other therapy. Bone marrow aspirates showed post-transplant mixed chimerism during engraftment, and became completely donor-derived after a series of GVHD symptoms, without subsequent donor lymphocyte infusion. Our results suggest that non-myeloablative allogeneic PBSCT could be a good alternative for patients suffering from multidrug resistant Waldenström's macroglobulinemia. Bone Marrow Transplantation (2001) 28, 609-611.
Waldenström's macroglobulinemia is a chronic B cell lymphoproliferative disorder characterized by bone marrow infiltrates of plasmacytoid lymphocytes producing abundant monoclonal macroglobulin. There have been some applications of high-dose chemotherapy followed by stem cell transplantation for the disease. [1] [2] [3] However, it is still controversial whether this treatment strategy could be as efficient as with most low grade lymphomas. Although a graftversus-tumor effect associated with allogeneic bone marrow transplantation could provide benefit, 4 most patients with this disorder are too old to tolerate the high-dose chemo-radiotherapy associated with the conventional transplantation procedures.
Allogeneic non-myeloablative stem cell transplantation has been recently developed, 5 and this employs short-term immunosuppression with fludarabine and less toxic chemotherapeutic agents compared with the myeloablative regimens. 6 To our knowledge, there have been no previous papers concerning non-myeloablative stem cell transplantation for Waldenström's disease. In this paper, we report an elderly (62-year-old) male patient with life-threatening severe pancytopenia due to Waldenström's macroglobulinemia who received non-myeloablative allogeneic peripheral stem cell transplantation. Although the patient had been treated with various chemotherapeutic agents for 5 years and became refractory to them, this transplantation resulted in a remarkable improvement in his condition and regression in his disease.
Case report
In November 1992, a 55-year-old man was admitted to our hospital with severe bleeding tendency. Peripheral blood examination revealed pancytopenia (white blood cell (WBC) of 3.1 ϫ 10 9 /l, hemoglobin (Hb) of 72 g/l, and platelets of 51 ϫ 10 9 /l), and showed marked increase in serum IgM level (15.2 g/l). Monoclonal expansion of IgMkappa paraprotein was confirmed, and bone marrow aspirates showed marked infiltration of immunoblastic, plasmacytoid lymphocytes (93.6% of total cell count). No lytic bone lesion was found. He was diagnosed as having Waldenström's macroglobulinemia and treated with plasmapheresis and melphalan-prednisolone therapy, which maintained the level of IgM (Ͻ1.0-1.5 g/l) and the number of abnormal cells (Ͻ40%) for 5 years. However, in July 1998, the cytopenia progressed and abnormal cells in bone marrow increased again (40-60%). Combination chemotherapy such as VAD (vincristine, adriamycin and dexamethasone) or alpha-interferon made no improvement. Finally, in October 1999, his cytopenia became life-threatening: daily administration of recombinant human (rh) G-CSF could only yield a WBC level of 0.4-0.5 ϫ 10 9 /l with 5-6% of neutrophils; his platelet counts were Ͻ10 ϫ 10 9 /l even with daily transfusion of concentrated platelets. His bone marrow was almost completely replaced with abnormal cells (98.8%), although the serum level of IgM did not increase (0.845 g/l).
This uncontrollable cytopenia and the multi-drug resistance of malignant cells made us consider bone marrow replacement therapy for him. Because of his age and risk of infection, a non-myeloablative procedure would be more suitable than ordinary myeloablative regimens, and PBSCT should be better because it would be able to provide early recovery in his WBC level. In December 1999, with his agreement and approval of the hospital committee, he received non-myeloablative conditioning that consisted of fludarabin (30 mg/m 2 once daily i.v. for 4 consecutive days) and melphalan (140 mg/m 2 for 1 day). 7 After that, unmanipulated allogeneic PBSCs (3.2 ϫ 10 6 /kg CD34 ϩ cells) were transfused from his HLA-matched sibling (53-year-old male) who received mobilization by rhG-CSF (filgrastim, (200 g/m 2 ϫ 2) ϫ 4 days). GVHD prophylaxis was done with cyclosporine (CyA). Intravenous rhG-CSF 300 g/m 2 was administered daily from day ϩ4 until the number of WBC exceeded 10 ϫ 10 9 /l. The transplantation was followed by sustained hematological engraftment, with neutrophils exceeding 0.5 ϫ 10 9 /l by day ϩ15, and platelets exceeding 50 ϫ 10 9 /l by day ϩ25. On day ϩ29, bone marrow aspirates still contained 42.8% lymphocytes, some of which showed abnormal morphology, and DNA analysis of variable number of tandem repeats (VNTR) revealed mixed chimerism in them ( Figure  1 ). The post-transplant course was uneventful until day ϩ70 when the patient developed GVHD involving skin (as manifested by macular-papular rash), lungs (as showed by interstitial pneumonia) and liver (as determined by mildly elevated AST, ALT and ALP, and confirmed by liver biopsy) with a Karnofsky performance status of 90%. Dose escalation of CyA (trough level of CyA increased from 80-100 ng/ml to 200-250 ng/ml) with methylprednisolone pulse therapy (40 mg/kg/day ϫ 2 days) was administered. The methylprednisolone was then tapered and withdrawn. By day ϩ100, the skin eruption had subsided, the lung involvement had been alleviated, and the elevated hepatic enzymes had declined toward normal levels. After resolution of the GVHD, CyA was tapered and nearly completely withdrawn at 5 months after the transplantation. Following chronic GVHD, VNTR analysis on day ϩ162 revealed that hematopoietic cells in bone marrow aspirates were all donor-derived ( Figure 1 ). Nucleated cell counts of the aspirates were 41 ϫ 10 9 /l, and 31.2% of the cells were lymphocytes, all of which showed no abnormal phenotype.
Five months after the transplant, the patient remains well with WBC of 2.1 ϫ 10 9 /l, Hb of 93 g/l and platelets of 23 ϫ 10 9 /l, without rhG-CSF and blood transfusion.
Discussion
Waldenström's macroglobulinemia is characterized by malignant proliferation of lymphocytes that produce monoclonal IgM. 8 The disorder is most commonly seen in the fifth and sixth decade. Although it is usually treated with alkylating agents and plasmapheresis, the prognosis is poor when it becomes refractory to chemotherapeutic agents.
In the present case, poor response to various chemotherapeutic agents had resulted in life-threatening severe pancytopenia and marked expansion of abnormal lymphocytes in the marrow. Non-myeloablative allogeneic stem cell transplantation was therefore considered as an option. Based on feasibility reports in multiple myeloma and low grade lymphoid malignancies, 6, 7 we have shown that non-myeloablative allogeneic peripheral blood stem cell transplantation could be performed for the patient with Waldenström's macroglobulinemia, who could not receive myeloablative chemotherapy because of its regimen-related toxicity. It is notable that we could successfully relieve the patient of life-threatening severe pancytopenia. On the other hand, we identified the reduction of abnormal cell counts in bone marrow, the disappearance of abnormal phenotypic cells, and the change of mixed-type DNA chimerism to complete donor-type chimerism after a series of GVHD without donor lymphocyte infusions. This may suggest the therapeutic potential of a graft-versus-tumor effect on this disorder. Hence, in some other cases, subsequent donor lymphocyte infusion would provide more benefit. Evaluation of graft-versus-tumor effect on Waldenström's disease will be needed in the future.
In summary, we suggest that non-myeloablative allogeneic stem cell transplantation might be a promising alternative treatment in the management of patients with Waldenström's macroglobulinemia. Some refractory cases could benefit from this treatment strategy.
